Aging processes and the development of osteoarthritis

Department of Internal Medicine, Section of Molecular Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
Current opinion in rheumatology (Impact Factor: 5.07). 10/2012; 25(1). DOI: 10.1097/BOR.0b013e32835a9428
Source: PubMed

ABSTRACT PURPOSE OF REVIEW: Aging is a primary risk factor for the development of osteoarthritis and the understanding of how aging processes contribute to the development of osteoarthritis is an important area of active research. The most recent literature in this area was reviewed in order to update investigators on the status of the field. RECENT FINDINGS: The field is beginning to move beyond a cartilage focus to include other joint tissues relevant to osteoarthritis such as ligaments, meniscus, and bone. Synovitis also appears to play a role in osteoarthritis but has not been a focus of aging studies. Studies in small animals, including mice and rats, demonstrate age-related changes that can contribute to osteoarthritis and show that animal age is a key factor to be considered in interpreting the results of studies using surgically induced models of osteoarthritis. There is accumulating evidence that cellular processes such as damage-induced cell senescence contribute to osteoarthritis and a growing body of literature on the role of epigenetic regulation of gene expression in aging and osteoarthritis. SUMMARY: Not all osteoarthritis is due to aging processes in joint tissues, but the age-related changes being discovered certainly could play a major contributing role.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Osteoarthritis (OA) is a painful and life-altering disease that severely limits the daily activity of millions of Americans, and is one of the most common causes of disability in the world. With obesity on the rise and the world's population living longer, the prevalence of OA is expected to increase dramatically in the coming decades, generating burdensome socioeconomic costs. This review summarizes current pharmaceutical, non-pharmaceutical, and prospective new treatments for OA, with primary focus on the dietary supplement Avocado/Soybean Unsaponifiables (ASU). ASU modulates OA pathogenesis by inhibiting a number of molecules and pathways implicated in OA. Anticatabolic properties prevent cartilage degradation by inhibiting the release and activity of matrix metalloproteinases (MMP-2,3,13) and increasing tissue inhibitors of these catabolic enzymes (TIMP-1). ASU also inhibits fibrinolysis by stimulating the expression of plasminogen activator inhibitor (PAI-1). Anabolic properties promote cartilage repair by stimulating collagen and aggrecan synthesis via inhibition of inflammatory cytokines such as IL1, IL6, IL8, TNF, ERK, and PGE2. Chondroprotective effects are mediated by correcting growth factor abnormalities, increasing TGFβ while decreasing vascular endothelial growth factor (VEGF) in synovial fluid. ASU also inhibits cholesterol absorption and endogenous cholesterol biosynthesis, which mediate reactive oxygen species pathology in chondrocytes. At the clinical level, ASU reduces pain and stiffness while improving joint function, resulting in decreased dependence on analgesics.
    Cartilage 01/2015; 6(1):30-44. DOI:10.1177/1947603514554992
  • [Show abstract] [Hide abstract]
    ABSTRACT: L’arthrose est la maladie articulaire la plus fréquente, caractérisée par un manque de traitements pharmacologiques efficaces. Ce constat nécessite d’avoir une approche neuve de cette affection. Les études récentes relatives à l’arthrose mettent en avant la vision pluritissulaire de cette maladie qui affecte non seulement le cartilage mais aussi la membrane synoviale, siège d’une inflammation, et l’os souschondral, impliqué précocement dans la maladie. L’ensemble des trois tissus participent à la dégradation de l’articulation et aux symptômes par le biais de médiateurs inflammatoires et d’enzymes protéolytiques. Cette vision de la maladie pourrait inciter à cibler spécifiquement ces tissus de manière pharmacologique. Par ailleurs, il n’y a pas une arthrose mais des arthroses directement en rapport avec les mécanismes initiateurs : ainsi différencie-t-on l’arthrose lié à l’obésité, l’arthrose post-traumatique et l’arthrose liée au vieillissement. Ces trois phénotypes sont caractérisés par une dégradation articulaire, mais les mécanismes y aboutissant sont certainement propres à chacun d’entre eux. L’arthrose liée à l’obésité est maintenant intégrée au sein d’un phénotype plus vaste, l’arthrose métabolique, compte tenu des associations épidémiologiques entre arthrose et syndrome métabolique. Les liens entre arthrose et diabète sont aussi particulièrement probants tant au plan clinique qu’au plan fondamental. Cette nouvelle vision de la maladie devrait aboutir à des traitements spécifiques de chacun de ces phénotypes. Abstract Osteoarthritis (OA) is the most frequent joint disorder, characterized by a lack of efficient pharmacological treatment. New approaches are thus needed. Recent studies support the hypothesis that OA is a pluritissular disease, affecting not only the cartilage but also synovial membrane that is inflamed and sub-chondral bone, early involved. All these 3 tissues are involved in joint degradation and symptoms through inflammatory mediators and proteolytic enzymes. Likewise, such a new view may open towards new tissue-specific pharmacological treatments. Moreover, there is no one OA but several OA directly in connection with the different risk factors. We thus differentiate obesity-related, injury-related and aging-related OA. Joint degradation is common to all OA phenotypes but pathophysiological mechanisms may be different. Obesity-related OA now belongs to a wider phenotype called “metabolic OA” since OA and metabolic syndrome are epidemiologically associated. Diabetes mellitus and OA are also tightly linked clinically and pathophysiologically. This new approach of the disease should lead to specific targeted therapies of each of these phenotypes.
    Douleur et Analgésie 03/2015; 28(1):20-25. DOI:10.1007/s11724-015-0409-4 · 0.09 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Vitamin K-dependent proteins, including the mineralization inhibitor matrix-gla protein (MGP), are found in joint tissues including cartilage and bone. Previous studies suggest low vitamin K status is associated with higher osteoarthritis (OA) prevalence and incidence. To clarify what joint tissues vitamin K is relevant to in OA, we investigated the cross-sectional and longitudinal association between vitamin K status and knee OA structural features measured using MRI. Plasma phylloquinone (PK, vitamin K1) and dephosphorylated-uncarboxylated MGP ((dp)ucMGP) were measured in 791 older community-dwelling adults who had bilateral knee MRIs (mean±SD age=74±3y; 67% female). The adjusted odds ratios (and 95% confidence intervals) [OR(95%CI)] for presence and progression of knee OA features according to vitamin K status were calculated using marginal models with generalized estimating equations, adjusted for age, sex, BMI, triglycerides and other pertinent confounders. Longitudinally, participants with very low plasma PK (<0.2nM) were more likely to have articular cartilage and meniscus damage progression after 3 years [OR(95%CIs): 1.7(1.0-3.0), 2.6(1.3-5.2) respectively] compared to sufficient PK (≥1.0nM). Higher plasma (dp)ucMGP (reflective of lower vitamin K status) was associated with higher odds of meniscus damage, osteophytes, bone marrow lesions, and subarticular cysts cross-sectionally [ORs(95%CIs) comparing highest to lowest quartile: 1.6(1.1-2.3); 1.7(1.1-2.5); 1.9(1.3-2.8); 1.5(1.0-2.1), respectively]. Community-dwelling men and women with very low plasma PK were more likely to have progression of articular cartilage and meniscus damage. Plasma (dp)ucMGP was associated with presence of knee OA features but not progression. Future studies are needed to clarify mechanisms underlying vitamin Ks role in OA. Copyright © 2014. Published by Elsevier Ltd.
    Osteoarthritis and Cartilage 12/2014; 23(3). DOI:10.1016/j.joca.2014.12.008 · 4.66 Impact Factor